VanEck非必需消費品TruSector主動型ETF TRUD 深 滬
已收盤 05-08 16:00:00 美东时间
27.105
+0.153
+0.57%
華盛通- 最 高27.24
- 今 開27.19
- 成交量 4.05万股
- 最 低 27.06
- 昨 收 26.9518
- 總市值 3740.49万
- 52周最高 27.4545
- 市盈率 靜 --
- 換手率 2.93%
- 52周最低 22.8345
- 委 比 71.43%
- 總股本 138.00万
- 歷史最高 27.4545
- 量 比 1.48
- 振 幅 0.67%
- 歷史最低 22.8345
- 每 手 1
- 風險率 0.92%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多FDA grants priority review to Merck’s Keytruda-Padcev for cisplatin-eligible bladder cancer
FDA grants priority review to Merck’s Keytruda-Padcev for cisplatin-eligible bladder cancer FDA granted priority review for Merck sBLA seeking KEYTRUDA, KEYTRUDA QLEX use with Padcev in perioperative treatment of cisplatin-eligible muscle-invasive bladder cancer. PDUFA target action date set for Aug
04-20 18:48
Adagene's Muzastotug Triplet Regimens Show Superior Response Rates In HCC And MSS CRC, Highlighting Improved Anti-CTLA-4 Tumor-Targeting At AACR 2026
Triple combination of muzastotug + atezolizumab + bevacizumab resulted in much higher overall response rates (ORR) compared to the atezolizumab + bevacizumab control arm (66.7% vs. 32.5%, respectively by Investigator per
04-18 04:03
Merck Says EU Approves KEYTRUDA, In Combination With Paclitaxel, With Or Without Bevacizumab, For Treatment Of Platinum-Resistant Epithelial Ovarian, Fallopian Tube Or Primary Peritoneal Carcinoma In Adults
The KEYTRUDA regimen is the first and only PD-1 inhibitor-based treatment approved in the European Union for these patientsApproval supported by data from the Phase 3 KEYNOTE-B96 trial in which the KEYTRUDA regimen
04-02 18:48
Pyxis Oncology FY 2025 R&D expenses rose 25.45% to USD 74 million, net loss widened to USD 79.62 million
Pyxis Oncology FY 2025 R&D expenses rose 25.45% to USD 74 million, net loss widened to USD 79.62 million Pyxis published a press release providing a business update and reporting fourth quarter and full-year 2025 financial results. Full-year revenue fell 13.9% to USD 13.9 million, while R&D expense
03-23 19:07
Citius Oncology Announces Data From Phase 1 Clinical Study Of Direct T-Regulatory Cell Depletion Activity Of LYMPHIR Shows 24% Objective Response Rate, 48% Clinical Benefit Rate In Participants With Recurrent Or Refractory Gynecologic Cancers
Citius Oncology, Inc. ("Citius Oncology") (NASDAQ:CTOR), an oncology‑focused biopharmaceutical company and majority‑owned subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (NASDAQ:CTXR), today announced
03-10 20:49
VanEck Targets India Growth Surge With New ETF As Investors Reassess Emerging Markets Exposure
VanEck launched an active India ETF and a communications sector ETF, targeting emerging markets growth and reducing sector tracking distortions.
02-25 04:38
BRIEF-Lassonde Industries Announces CFO Succession Plan
BRIEF-Lassonde Industries Announces CFO Succession Plan Feb 19 (Reuters) - Lassonde Industries Inc LASa.TO : LASSONDE INDUSTRIES INC. ANNOUNCES CHIEF FINANCIAL OFFICER SUCCESSION PLAN LASSONDE INDUSTRIES INC - APPOINTS FRANCIS TRUDEAU AS EXECUTIVE VICE-PRESIDENT FINANCE LASSONDE INDUSTRIES INC: NOMI
02-20 07:00
BRIEF-Health Canada Approves Keytruda SC™, A Subcutaneous Formulation Of Pembrolizumab Across Multiple Cancer Indications
BRIEF-Health Canada Approves Keytruda SC™, A Subcutaneous Formulation Of Pembrolizumab Across Multiple Cancer Indications Feb 17 (Reuters) - HEALTH CANADA : HEALTH CANADA APPROVES KEYTRUDA SC™, A SUBCUTANEOUS FORMULATION OF PEMBROLIZUMAB ACROSS MULTIPLE CANCER INDICATIONS (( Reuters.Briefs@thomsonre
02-18 01:30
Merck's KEYTRUDA SC Receives Health Canada Approval
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that Health Canada has approved KEYTRUDA SC™ (pembrolizumab injection), a new subcutaneous formulation of
02-18 00:03
FDA Approves Merck's KEYTRUDA Regimen for Platinum-Resistant Ovarian Cancer
FDA Approves Merck's KEYTRUDA Regimen for Platinum-Resistant Ovarian Cancer The U.S. Food and Drug Administration (FDA) has approved Merck & Co. Inc.'s KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) in combination with paclitaxel, with or without bevaciz
02-11 19:45
